Kennesaw State University
Kennesaw, Georgia, 30144, United States
NCT Number: NCT05371340
Quercetin is a plant-based flavonoid that is naturally found in many fruits and vegetables, and is considered to be a potent antioxidant with several expected health benefits such as anti-inflammatory effects and bone-conserving properties. Participants will supplement with either Quercetin, or placebo, for 90-days with pre- and post-testing visits.
Looking for future studies?
Notify Me45 year–75 year
Female
Interventional
Not applicable
Kennesaw, Georgia, 30144, United States
Quercetin is a plant-based flavonoid that is naturally found in many fruits and vegetables such as onions, apples, berries, green tea, and red wine and is currently an FDA approved supplement. Quercetin is considered to be a potent antioxidant with several expected health benefits. Both in vivo and in vitro studies have demonstrated that quercetin acts as a potent natural osteogenic agent with benefits that include anti-inflammatory effects and bone-conserving properties. Quercetin is suggested to protect against bone loss by inhibiting bone resorption and stimulating bone formation which is indicated by an increase in bone mineral density and bone formation markers such as osteocalcin.
The purpose of this study is to investigate the effects of quercetin supplementation on bone, specifically on bone turnover markers, in postmenopausal women. The interplay between cytokines (i.e., IL-6, CRP, and TNF-alpha) and bone turnover markers was also considered.
In a double-blind, placebo-controlled fashion, we aimed to recruit 50, healthy, postmenopausal women between the ages of 45-75 years to participate in a 90-day supplement trial. Participants will be randomly assigned to one of two supplement groups: 1) quercetin 500 mg, once per day, or 2) placebo (methyl cellulose E4M) 500 mg, once per day for 90-days.
Participants will be asked to visit the laboratory (KSU Human Performance Laboratory) on 2 separate occasions for pre- and post-testing visits consisting of body composition measurements and blood draws by a CITI approved/IRB approved research team member trained in phlebotomy under the supervision of Dr. VanDusseldorp.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Once-daily 500 mg Quercetin
Once-daily 500 mg methylcellulose 9E4M)
Time frame: 90-days
Bone formation marker
Time frame: 90-days
Procollagen type-I N-terminal propeptide. Bone formation marker.
Time frame: 90-days
Type-I collagen cross-linked C-terminal telopeptide. Bone resorption marker.
Time frame: 90-days
Interleukin-6 inflammatory marker.
Time frame: 90-days
Tumor necrosis factor-alpha inflammatory marker
Time frame: 90-days
C-reactive protein inflammatory marker.
Time frame: 90-days
Fasting blood glucose
Time frame: 90-days
Total, lumbar, right and left femur, and left forearm bone mineral density
Time frame: 90-days
body fat percentage
Time frame: 90-days
Physical function test
Time frame: 90-days
Physical function test
Kennesaw State University
Other
The Efficacy of Quercetin Supplementation on Bone Turnover Markers, Inflammatory Markers, Body Composition, and Physical Function in Post-Menopausal Women
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05493761
Bone Diseases, Bone Diseases, Metabolic
Thessaloniki, Greece
View Trial DetailsNCT07717788
Bone Diseases, Bone Diseases, Metabolic
Najaf, Iraq
View Trial DetailsNCT06375668
Bone Density, Low, Bone Diseases
Bytom, Poland
View Trial DetailsNCT05395091
Bone Diseases, Bone Diseases, Metabolic
Plovdiv, Bulgaria
View Trial Details